Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) Equity Ratio (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Equity Ratio readings, the most recent being 0.84 for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio fell 0.91% year-over-year to 0.84, compared with a TTM value of 0.84 through Dec 2025, down 0.91%, and an annual FY2025 reading of 0.84, down 0.91% over the prior year.
  • Equity Ratio hit 0.84 in Q4 2025 for Lisata Therapeutics, up from 0.8 in the prior quarter.
  • The five-year high for Equity Ratio was 0.93 in Q2 2023, with the low at 0.8 in Q3 2025.
  • Median Equity Ratio over the past 3 years was 0.88 (2024), compared with a mean of 0.87.
  • The largest YoY upside for Equity Ratio was 0.91% in 2025 against a maximum downside of 8.78% in 2025.
  • Year by year, Equity Ratio stood at 0.88 in 2023, then decreased by 3.52% to 0.84 in 2024, then decreased by 0.91% to 0.84 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.84, 0.8, and 0.83 for Q4 2025, Q3 2025, and Q2 2025 respectively.